(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) fell by a staggering 15.07% in 7 days from $0.73 to $0.62 at 10:42 EST on Wednesday, after two consecutive sessions in a row of losses. NASDAQ is jumping 0.28% to $11,456.80, following the last session’s downward trend.

Xenetic Biosciences’s last close was $0.64, 73.37% below its 52-week high of $2.42.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical firm that focuses on advancing XCART, a customized chimeric receptor T cell (CART) platform technology designed to target specific patient-specific tumour neoantigens. It is involved in research and development of oncology therapies and biologic drugs. Cell-based therapies that target the B-cell receptor are developed to treat B-cell lymphomas. By partnering with pharmaceutical and biotechnology companies, it is also using PolyXen, their proprietary drug delivery platform. Takeda Pharmaceutical Co. Ltd. and Serum Institute of India Limited have signed collaboration agreements. Xenetic Biosciences, Inc. has its headquarters in Framingham, Massachusetts.


Today’s last reported volume for Xenetic Biosciences is 5087 which is 89.42% below its average volume of 48092.

The company’s growth estimates for the ongoing quarter and the next is 20% and 15.4%, respectively.

Xenetic Biosciences’s Revenue

Year-on-year quarterly revenue growth grew by 103.4%, now sitting on 1.36M for the twelve trailing months.


Xenetic Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.25%, a negative 1.08%, and a positive 3.12%, respectively.

Xenetic Biosciences’s highest amplitude of average volatility was 3.69% (last week), 3.14% (last month), and 3.12% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Xenetic Biosciences’s stock is considered to be overbought (>=80).

Xenetic Biosciences’s Stock Yearly Top and Bottom Value

Xenetic Biosciences’s stock is valued at $0.62 at 10:42 EST, way under its 52-week high of $2.42 and way above its 52-week low of $0.45.

Xenetic Biosciences’s Moving Average

Xenetic Biosciences’s worth is way under its 50-day moving average of $0.83 and way under its 200-day moving average of $0.95.

More news about Xenetic Biosciences (XBIO).


Please enter your comment!
Please enter your name here